Welsh, Carson, Anderson & Stowe XII, L.P. sold 10,000,000 shares of INNV (indirect holdings)

Welsh, Carson, Anderson & Stowe XII, L.P. sold 10,000,000 indirectly-held shares of InnovAge Holding Corp. (INNV) on 2026-09-24. Filed jointly with WCAS CO-INVEST ASSOCIATES LLC (10% owner), Welsh, Carson, Anderson & Stowe XII Delaware, L.P. (10% owner), Welsh, Carson, Anderson & Stowe XII Delaware II, L.P. (10% owner), Welsh, Carson, Anderson & Stowe XII Cayman, L.P. (10% owner), WCAS XII Co-Investors LLC (10% owner), WCAS MANAGEMENT CORP (10% owner), WCAS - CO-INVEST HOLDCO, L.P. (10% owner), WCAS XII ASSOCIATES LLC (10% owner) and WCAS XII ASSOCIATES CAYMAN, L.P. (10% owner).

Original reporting
SEC EDGAR · Welsh, Carson, Anderson & Stowe XII, L.P., WCAS CO-INVEST ASSOCIATES LLC, Welsh, Carson, Anderson & Stowe XII Delaware, L.P., Welsh, Carson, Anderson & Stowe XII Delaware II, L.P., Welsh, Carson, Anderson & Stowe XII Cayman, L.P., WCAS XII Co-Investors LLC, WCAS MANAGEMENT CORP, WCAS - CO-INVEST HOLDCO, L.P., WCAS XII ASSOCIATES LLC, WCAS XII ASSOCIATES CAYMAN, L.P.
Published Sep 28, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INNV
Bearish
medium confidence
Mentioned
$INNV
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INNVBearishLow
01

Why it matters

The filing reveals a substantial block sale by a major shareholder, which can influence short‑term price dynamics.

02

Market read

Insider sell of 10M shares may trigger short‑term bearish pressure on INNV.

03

What to watch

No disclosed price or reason; the insider may have liquidity needs unrelated to company outlook.

Relevance 6/10Novelty 7/10Timing: post-market today

Background

SEC Form 4 provides a primary source disclosure of insider transactions.

Company-level read

Ticker impact

$INNVBearishMedium confidence
Context

Form 4 filing shows WCAS sold 10,000,000 shares of InnovAge Holding Corp., reducing its stake but still holding 102,576,555 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

10M shares represent a sizable block from a 10% owner; such sales often precede short‑term price weakness.

Market effects

May weigh on the biotech/healthcare sector if investors view insider selling as a red flag.

Limited to US markets where INNV trades.

Minimal global impact beyond sector sentiment.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • InnovAge Holding Corp.

    Biotech firm listed on Nasdaq under ticker INNV.

  • Welsh, Carson, Anderson & Stowe XII, L.P.

    Private equity firm acting as a 10% owner of INNV.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INNVMed

InnovAge settles DOJ civil claims for $37 million

InnovAge Holding Corp. (INNV) settled civil claims with the DOJ for $37 million, covering alleged conduct from 2016 to 2022. The company did not admit wrongdoing. InnovAge provides senior healthcare programs and has invested in compliance and operations. As of September 2026, it served 8,420 participants across 20 centers in six states.

$INNVMed

InnovAge (INNV) Q1 2027 Earnings Call Transcript

InnovAge (INNV) reported Q1 2027 revenue of $264.8M, up 12.1% YoY, and adjusted EBITDA of $31.3M, up 75%. The company cited growth in census and profitability, investments in clinical and operational capabilities, and plans for expansion. Management discussed the impact of the V28 Medicare risk adjustment model, noting differences between PACE and Medicare Advantage.

$INNVMed

What InnovAge (INNV) Said on Its Q1 Earnings Call

InnovAge (INNV) reported Q1 cost of care rose 12.7% to $85.5M, citing growth and higher expenses. The company is investing in care teams and technology to reduce costs. InnovAge reaffirmed its fiscal 2027 guidance, expecting revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. Medicare rates are expected to increase 1.5%-2% from Jan 1, 2024.

$INNVHigh

INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026

InnovAge Holding Corp. (INNV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026 DENVER, CO., November 3, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare